Knowledge center
The place to find all the most innovative research and information on novel biologics and biosimilars.
December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG, our joint venture, regarding the licensing, supply, and commercialization agreement with Zydus Lifesciences Ltd. for NUFYMCO® (biosimilar ranibizumab), an interchangeable biosimilar to Lucentis®, in the United States. This strategic collaboration underlines the strength and expertise of Polpharma Biologics...
Latest news
Find out about all the latest developments of our portfolio and our partners products and other news from Polpharma Biologics.
December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG, our joint venture, regarding the licensing, supply, and commercialization agreement with Zydus Lifesciences Ltd. for NUFYMCO® (biosimilar ranibizumab), an interchangeable biosimilar to Lucentis®, in the United States. This strategic collaboration underlines the strength and expertise of Polpharma Biologics...
December 10, 2025 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases...
November 17, 2025 – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with...
Zurich, Switzerland – October 21, 2025 – Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration...
Downloads
You can find all the latest presentations, brochures and fact sheets below covering our solutions and portfolio.
Polpharma Biologics S.A. is required to prepare and publish information on the executed tax strategy in order to fulfill the obligation set forth in Article 27c paragraph 1 in connection with Article 27b paragraph 2 points 1 and 2 of the Corporate Income Tax Act of February 15, 1992. We invite you to read the document.
This Code of Conduct is the first step to showing dedication to upholding continuous excellence in both business and ethical terms, and showing our care and dedication to products, clients and success.
Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward building the company’s international scientific cooperation platform.
